Since 2000, ClinicalTrials.gov has served as a public registry of clinical studies. We track the number of drug and biological trials registered over time, as one proxy for progress in drug development.
AI could speed up drug target discovery and trial design, which could lead to more new drug trials. Registrations on ClinicalTrials.gov provide a monthly count of trials entering the drug development pipeline, dating back to 2000.
We count interventional studies of drugs and biologics using the ClinicalTrials.gov API, across all phases, by the month their record was first posted. Note that the first-posted date is when a trial’s record appeared on the registry, not when the trial started.
ClinicalTrials.gov is the world’s largest public clinical trial registry, though coverage is incomplete: not all trials are legally required to be registered, and compliance among those that are is likely imperfect. It is managed in the US but also captures international trials.
Source: ClinicalTrials.gov (US National Library of Medicine).
Our charts, text and processing are available under the Creative Commons Attribution license. The underlying data comes from ClinicalTrials.gov (US National Library of Medicine) (https://clinicaltrials.gov/) and is subject to its own licence or terms.
Since 2000, ClinicalTrials.gov has served as a public registry of clinical studies. We track the number of drug and biological trials registered over time, as one proxy for progress in drug development.